Skip To Main Content
Nicole DeFeudis on Muck Rack

Nicole DeFeudis

Verified
Massachusetts
As seen in: Endpoints News, WBZ-TV (Boston, MA), Boston.com, U.S. News and World Report, The Boston Globe, WBUR News, BioMedWorks’ Newsletter, Boston Herald, The Virginian-Pilot, Worcester Telegram & Gazette, WWLP-TV (Chicopee, MA) and
Biopharma reporter @endpts | ndefeudis@endpoints.news

Get in touch with Nicole

Contact Nicole, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more

|
By Max Gelman Verified, Nicole DeFeudis Verified
| Endpoints News Verified
August 22, 2026 06:00 AM EDT Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more Welcome back to Endpoints Weekly! Merck and Moderna dominated the headlines this week with topline results for their personalized cancer vaccine. Check out our team’s … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

|
By Nicole DeFeudis Verified
| Endpoints News Verified
Stéphane Bancel, Moderna CEO (Hollie Adams/Bloomberg via Getty Images) August 19, 2026 02:58 PM EDT For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars Moderna has been saying for years that it would diversify its portfolio beyond infectious diseases. Investors were waiting for late-stage proof. On Wednesday, they got … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom

|
By Nicole DeFeudis Verified
| Endpoints News Verified
Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom After a lower court rejected Teva’s case last fall, a federal appeals court has revived part of the drugmaker’s lawsuit against Medicare negotiations. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?
See all 3,045 licensed articles (3,064 Total)